Characterization of distinct stages during the differentiation of human CD69+CD3+ thymocytes and identification of thymic emigrants.
During thymocyte development, CD69 expression is induced at an early stage of positive selection. To examine the differentiation of human CD69+CD3+ thymocytes, discrete phenotypes were defined by the relative expression of CD69, CD27, CD1, and CD45RA/RO: CD3+CD69- thymocytes were CD27-CD1+CD45RA-/RO+ (phenotype I), whereas the CD3+ CD69+ population could be subdivided into CD27-CD1+CD45RA-/RA+ (phenotype II), CD27+CD1+CD45RA-/RO+ (phenotype III), CD27+CD1-CD45RA-/dull/RO+ (phenotype IV), and CD27+CD1-CD45RA+/ROdull (phenotype V) thymocytes. Phenotype I thymocytes were CD4+CD8 alpha beta + double positive (DP). Phenotype II thymocytes contained DP and CD4+CD8 alpha dullCD8 beta- cells, whereas phenotype III thymocytes were DP and mostly CD4dullCD8 alpha beta+, indicating that CD27 on DP cells may be a marker for CD8-committed cells. Results obtained with SCID-hu mice, transplanted with human fetal thymus and liver, showed that immature human CD69-CD3+ thymocytes were corticosteroid-sensitive, whereas essentially all CD69+CD3+ cells were resistant. During differentiation of one cohort of corticosteroid-resistant CD69+CD3+ thymocytes, phenotype II and III thymocytes, disappeared within a week, whereas the percentage of phenotype IV and especially V thymocytes increased, suggesting that the latter represent the end stages in differentiation. Recent thymic emigrants in SCID-hu mice were identified as CD69-CD27+CD1-CD45RA-/dull/RO+ or CD45RA+/ROdull cells. Because phenotype IV and phenotype V thymocytes rapidly lose CD69 expression in cell culture, these thymocytes are probably the cells that are exported from the thymus. In conclusion, after the acquisition of CD69, thymocyte differentiation appears to continue in an ordered pattern, and cells that eventually leave the thymus are CD69-CD1-CD45RA+ or CD45RA-/dull.
Vanhecke
D
D
Department of Clinical Biology, Microbiology and Immunology, University Hospital, Ghent, Belgium.
Leclercq
G
G
Plum
J
J
Vandekerckhove
B
B
D000818:Animals; D015703:Antigens, CD / Q000032:analysis*; D018949:Antigens, CD1; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis*; D017252:CD3 Complex / Q000032:analysis*; D015704:CD4 Antigens / Q000032:analysis; D016827:CD8 Antigens / Q000032:analysis; D002454:Cell Differentiation; D002648:Child; D002675:Child, Preschool; D003348:Cortisone / Q000494:pharmacology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D037181:Lectins, C-Type; D051379:Mice; D016513:Mice, SCID; D013601:T-Lymphocytes / Q000276:immunology / Q000502:physiology*; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000032:analysis; D000099192:CD69 Antigens
D015703:Antigens, CD; D018949:Antigens, CD1; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D003348:Cortisone; D037181:Lectins, C-Type; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D000099192:CD69 Antigens